Pfizer Inc. $PFE Shares Sold by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 8.7% in the second quarter, Holdings Channel reports. The institutional investor owned 258,994 shares of the biopharmaceutical company’s stock after selling 24,712 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Pfizer were worth $6,237,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in PFE. Plato Investment Management Ltd lifted its position in shares of Pfizer by 41.5% during the 2nd quarter. Plato Investment Management Ltd now owns 225,254 shares of the biopharmaceutical company’s stock valued at $5,392,000 after buying an additional 66,017 shares in the last quarter. Cura Wealth Advisors LLC increased its holdings in Pfizer by 5.8% in the 2nd quarter. Cura Wealth Advisors LLC now owns 21,140 shares of the biopharmaceutical company’s stock worth $509,000 after acquiring an additional 1,167 shares in the last quarter. Simplicity Wealth LLC increased its holdings in Pfizer by 144.2% in the 2nd quarter. Simplicity Wealth LLC now owns 109,120 shares of the biopharmaceutical company’s stock worth $2,628,000 after acquiring an additional 64,440 shares in the last quarter. Wealth Effects LLC raised its position in Pfizer by 2.6% during the second quarter. Wealth Effects LLC now owns 78,083 shares of the biopharmaceutical company’s stock worth $1,880,000 after acquiring an additional 2,008 shares during the period. Finally, Gould Asset Management LLC CA lifted its holdings in Pfizer by 16.5% during the second quarter. Gould Asset Management LLC CA now owns 9,062 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 1,283 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 0.8%

Shares of PFE opened at $28.00 on Friday. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75. The firm has a market capitalization of $159.59 billion, a P/E ratio of 36.84 and a beta of 0.34. The firm has a 50-day moving average price of $25.30 and a 200 day moving average price of $26.25. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the business posted $0.78 EPS. Pfizer’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer’s dividend payout ratio is currently 226.32%.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. UBS Group reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. Bank of America decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Guggenheim reduced their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a report on Friday, August 7th. Finally, Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.28.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.